Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Inflammation Marker Linked to Increased Cancer Death Risk

By LabMedica International staff writers
Posted on 28 Nov 2012
The measurement of blood levels of high-sensitive C-reactive protein in apparently cancer-free men could potentially help identify those at increased risk for death from cancer.

High-sensitive C-reactive protein (hs-CRP) is an important marker of inflammation has been linked to the initiation and progression of several types of cancer, as well as to the progression of atherosclerosis and cardiovascular disease. More...


Scientists at the Seoul National University Hospital (South Korea) retrospectively analyzed data from 33,556 individuals who had completed medical checkups and had been screened for blood hs-CRP at a health-screening center between May 1995 and December 2006. The average follow-up was 9.4 years, and during that time, 1,054 deaths from all causes and 506 deaths from cancer were recorded.

The hs-CRP levels were measured with a highly sensitive latex-enhanced immunoassay run on an automated chemistry analyzer (Hitachi; Tokyo, Japan). The investigators adjusted for several variables, including age, diabetes, smoking status and exercise habits and found that men with the highest level of hs-CRP in their blood, 3 mg /L or more, were 38% more likely to have died from any cause compared with men with the lowest hs-CRP level of 1 mg/L or less. They were also 61% more likely to have died from cancer. For women, after adjusting for a number of variables, no statistically significant association was observed for hs-CRP level and death from any cause or death from cancer.

Through analysis of associations between hs-CRP levels and site-specific cancers, the scientists found that a significant relationship existed only for lung cancer. After adjusting for multiple variables, individuals with the highest hs-CRP level were more than twice as likely to die from lung cancer compared with those with the lowest hs-CRP level. The association between hs-CRP levels and all-cause mortality and cancer mortality was stronger in lean individuals compared with those who were overweight.

Minseon Park, MD, PhD, MPH, the senior author of the study said, "We wanted to determine whether there was a relationship between a well-established marker of inflammation, high-sensitive C-reactive protein, and death from all causes, death from cancer or death from a site-specific cancer in Koreans." The study was published in the November 2012 edition of the journal Cancer Epidemiology, Biomarkers & Prevention.

Related Links:

Seoul National University Hospital
Hitachi



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.